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1. Introduction {#prca1977-sec-0050}
===============

Autoimmune hepatitis (AIH) is a global disease, which has a prevalence of 10--20 per 100 000 individuals and is seen more frequently among women (male to female ratio of 1:4). The peak incidence of disease occurs in the fourth or fifth decade of life.[1](#prca1977-bib-0001){ref-type="ref"} The etiology of AIH is not clear and is generally associated with heredity and environment.[2](#prca1977-bib-0002){ref-type="ref"} Two thirds of autoimmune cirrhosis (AIC) is mainly caused by chronic process of AIH, in which approximately one third of the adult patients and one half of the pediatric patients present with cirrhosis at diagnosis, and untreated patients generally advance to cirrhosis and liver failure.[3](#prca1977-bib-0003){ref-type="ref"}, [4](#prca1977-bib-0004){ref-type="ref"} Approximately one third of the patients have no clear history of hepatitis and are directly detected as AIC. Cirrhosis in AIH at any time during the course of disease is associated with a poor prognosis.[4](#prca1977-bib-0004){ref-type="ref"}, [5](#prca1977-bib-0005){ref-type="ref"} AIC can be developed into hepatocellular carcinoma or serious complications such as esophageal variceal bleeding, hepatic encephalopathy, which are harmful to people\'s life, bringing huge waste of medical resources and economic losses.[6](#prca1977-bib-0006){ref-type="ref"}

The diagnosis of AIC disease, remains challenging,[7](#prca1977-bib-0007){ref-type="ref"} which mainly depends on medical history, clinical symptoms, and radiological examinations, but once AIC can be confirmed, AIC has reached the middle or late stages, leading to irreversible liver damage, missing the best time for therapy, forcing the patients for transplantation. However, the early damage of cirrhosis is reversible and the treatment effect is good which can effectively prevent the deterioration of the disease process.[8](#prca1977-bib-0008){ref-type="ref"} Therefore, AIC focuses on early diagnosis and early treatment, but the biochemical indicators were not specific, which are easily confused with AIH and is difficult to distinguish with other diseases, such as serum aminotransferase, high gamma globulin, autoantibody IgG positive, which can also be found in AIH, viral hepatitis, drug‐induced hepatitis, or other immune diseases.[9](#prca1977-bib-0009){ref-type="ref"} There is no specific diagnostic markers for AIC.

Clinical Relevance {#prca1977-sec-0060}
------------------

Currently, the diagnosis of autoimmune cirrhosis (AIC) disease remains challenging, there are no specific diagnostic markers for AIC. In the present study, we first implemented isobaric tags for relative and absolute quantitation technique to identify the differentially expressed proteins in the serum of AIC compared to the normal controls. One hundred and eight differentially expressed proteins were identified and most of them were found to be involved in multiple functional groups, including ion binding activity, peptidase activity, and enzyme regulator activity. Moreover, we identified von Willebrand factor, insulin‐like growth factor‐binding protein complex acid labile subunit, transthyretin, adiponectin proteins as candidate biomarkers for AIC. These results are very helpful to elucidate the pathogenic mechanism of AIC.

Liver biopsy is still the most accurate and widely used method, by which cirrhosis can be diagnosed and staged. There are, however, notable disadvantages to this method of examination, including cost, risk of bleeding, and sampling error.[10](#prca1977-bib-0010){ref-type="ref"} So it is necessary to find specific biomarkers of AIC for early prevention, early diagnosis, and early treatment.

Isobaric tags for relative and absolute quantitation (iTRAQ) technology has been currently used as a powerful tool for global evaluation of protein expression about specific diseases or disease stages, which shows significantly improved sensitivity and repeatability when compared with the traditional 2D electrophoresis , and has been widely applied in studying biomarkers for various diseases.[11](#prca1977-bib-0011){ref-type="ref"} In this study, the general workflow is shown in Figure [1](#prca1977-fig-0001){ref-type="fig"}, we aim to first identify potential serum proteins as biomarkers in AIC because of the convenience of serum samples. Bioinformatics analysis of differentially expressed proteins indicated that these proteins might have important roles in a variety of cellular processes and structures, including stress, immune system process, vesicle‐mediated transport, and signal transduction.

![General work flow and summary of the present study. iTRAQ technology was applied to identify the differentially expressed proteins in autoimmune cirrhosis and normal controls. At the end of the study, we combined the results of bioinformatics analysis to identify vWF, adiponectin, IFGALS, and transthyretin proteins as candidate biomarkers for autoimmune cirrhosis.](PRCA-13-na-g001){#prca1977-fig-0001}

2. Experimental Section {#prca1977-sec-0070}
=======================

*Preparation of Serum Samples*: Blood samples were collected from 16 patients (12 women and 4 men) with autoimmune cirrhosis diagnosed according to the following criteria[12](#prca1977-bib-0012){ref-type="ref"}:1)excluding cirrhosis due to other causes; 2) AIH for at least half a year, or the clinical score reaching more than 15 points without AIH history; 3) B ultrasound indicated that the surface of liver was enhanced and thickened, not smooth or nodular, and the spleen enlarged or the vein widened; 4) hepatic hypofunction and 5) not treated with medication. The diagnosis of each enrolled patients was confirmed by liver biopsy. At the same time, patients were excluded if they had other diseases: 1) other cancers; 2) autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus; 3) severe infections; 4) basic diseases, such as diabetes, hypertension, coronary heart disease; 5) diseases of hematopoietic system, such as aplastic anemia, leukemi and 6) pregnancy. Another 16 matched (12 women and 4 men) blood samples from normal people were collected as controls. All the samples were provided by the Department of Infectious Diseases, Third Affiliated Hospital in Sun Yat‐sen University and separated by centrifugation at 800 × *g* for 30 min. Aliquots of serum were collected and stored at −80 °C. To reduce the individual differences, aliquots of serum samples from four randomly selected individuals in each group (AIC and healthy controls)were mixed to create eight pools. Groups n1, n2, n3, n4 (n = normal), p1, p2, p3, and p4 (p = patient) were formed.

Serum samples were processed using the ProteoPrep Blue Albumin Depletion Kit (Sigma, St. Louis, MO, USA), which selectively removes albumin and IgG from the serum sample according to the manufacturer\'s instructions. In order to depurate the protein extraction and determine the final protein concentration, the 2D Clean‐up Kit (GE Healthcare, UK) and 2D Quant Kit (GE Healthcare, London, UK) were used sequentially, following the manufacturer\'s instructions. Proteins were digested according to the FASP method.[13](#prca1977-bib-0013){ref-type="ref"} Protein samples (100 μg) were reduced using 2 μL of reducing agent and incubated at 60 °C for 1 h. Next, added 1 μL of cysteine‐blocking reagent at room temperature for 10 min using iTRAQ Reagent Multiplex Buffer Kit (AB Sciex, USA), and then transferred for ultrafiltration. Finally, 100 μL 1 [m]{.smallcaps} TEAB buffer was added and centrifuged at 12 000 × *g* for 20 min for three times. Trypsin (1 μg μL^−1^, 1:50, Progema, USA) was added to the samples for incubating at 37 °C for 16 h.

*Protein Labeling with iTRAQ*: iTRAQ labeling was performed according to the manufacturer\'s instructions (Applied Biosystems Sciex, \#4381664). Groups n1, n2, n3, n4, p1, p2, p3, and p4 were individually labeled with iTRAQ reagent (including n1‐iTRAQ 113 reagent, n2‐iTRAQ 114 reagent, n3‐iTRAQ 117 reagent, n3‐iTRAQ 118 reagent, p1‐iTRAQ 115 reagent, p2‐iTRAQ 116 reagent, p3‐iTRAQ 119 reagent, and p4‐iTRAQ 121 reagent).The labeled samples were allowed to incubate at room temperature for 2 h, then all the serum samples were mixed together and vacuum dried.

High pH Reverse Phase Fractionation: High pH reverse phase fractionation chromatography was carried out using a Dionex UltiMate 3000 HPLC system. The iTRAQ‐tagged peptides were reconstituted and loaded onto Gemini‐NX C18 columns (3 μm, 2 × 150 mm, 110 A, Phenomenex). The peptides were eluted with a linear gradient formed by buffer A (20 mm NH4HCO2, pH = 10) and buffer B (20 mm HCOONH4, 80% acetonitrile, pH = 10) for 100 min at a flow rate of 200 μL min−1. Twenty‐four fractions were collected at 1 min intervals, based on UV detection wavelength at 214/280 nm. Then all the fractions were dried individually and dissolved in the sample solution (0.1% formic acid and 2% acetonitrile) for nano LC--MS /MS analysis.

*LC--MS/MS Analysis by Q Exactive*: The nano LC--MS/MS was carried out using Q Exactive (Thermo Scientific) with the peptide recognition mode enabled. The peptide mixture was separated on the chromatographic column (75 um × 150 mm, packed with Acclaim PepMap RSLC C18, 2 μm, 100A) at a flow rate of 300 nL min−1. And then peptides were eluted from the HPLC column through the application of a linear gradient from 4% to 50 % solution (0.1% FA, 80% ACN) for 40 min. Finally, the eluted peptides were detected by Q Exactive and MS data were acquired using a data‐dependent top 20 method, dynamically choosing the most abundant precursor ions from the survey scan (350--1800 m/z, resolution of 70 000 at m/z 200) for high‐energy collisional dissociation (HCD; resolution of 17 500 at m/z 200, collision energy 30 eV) fragmentation with each component analysis for 60 min.

*Protein Identification and Data Analysis*: First, the raw files were converted to .mgf files by Proteome Discoverer 1.4 (Thermo Fisher Scientific). Then, Protein Pilot 5.0 (AB Sciex, USA) was used for protein identification and quantification analysis. Database searching parameters were as follows. Sample type: iTRAQ 8plex (Peptide Labeled), Cys alkylation: MMTS, ID focus: biological modification, digestion: trypsin, Search effort: thorough ID, FDR \<1%, T‐test was used to identify significant differences (p \< 0.05) in means between AIC and control with an average ratio‐fold change ≥1.5 or ≤0.66, a minimum of two peptide matches in common was confidently considered as differential expression of proteins. The coefficient of variation was used to evaluate the dispersion of the replicates within groups, and detected proteins with coefficient of variation ≤ 0.5 were considered reliable.

Bioinformatics Analysis: Bioinformatics analysis was carried out in order to better study the biological function of significantly altered proteins. GO annotation and enrichment analysis (http://www. geneontology.org) which includes three main modules---biological process, cellular component, and molecular function---was employed to categorize proteins into families and subfamilies with shared functions. Pathway analysis using KGEE (http://www.genome.jp/kegg/pathway.html) was used to take advantage of the current knowledge of biochemical pathways and protein--protein interaction networks using STRING database (http:// [www.string-db.org](http://www.string-db.org)) which is a database of known and predicted protein interactions, including direct (physical) and indirect (functional) associations.

Western Blot Analysis: Serum samples of the same amount of protein were separated by SDS‐PAGE and analyzed by western blot. In brief, proteins (60 ug) in the gels were transferred onto PVDF membranes (Roche). After blocking for nonspecific binding with 5% non‐fat milk, the membranes were incubated with primary antibodies against apoE (abcam, \#7613), apoA1 (abcam, \#7620), von Willebrand factor (vWF; CST, \#65707), insulin‐like growth factor‐binding protein complex acid labile subunit (IFGALS; abcam, \#85222), gelsolin (abcam, \#109014), adiponectin (CST, \#2789), transthyretin (TTR; abcam, \#92469), pIgR (abcam, \#96196) at 4 °C overnight, followed by the appropriate horse‐radish peroxidase‐conjugated secondary antibodies. All blots were visualized using ECL (Amersham Biosciences).Quantification was performed using ImageJ software.

*Statistical Data and Graphics*: The statistical analyses were performed using GraphPad Prism version 6.01 for Windows (GraphPad Software, La Jolla, California, USA; www.graphpad.com). Student\'s t‐test was applied for comparisons of quantitative data. The receiver operating characteristic (ROC) analysis with SPSS Statistics 20.0 was performed to evaluate sensitivity and specificity of each marker and their combination in AIC and AIH. For all analysis, p value \< 0.05 was considered to indicate statistical significance.

3. Results {#prca1977-sec-0080}
==========

3.1. Primary Data Analysis and Protein Identification {#prca1977-sec-0090}
-----------------------------------------------------

The goal of this study was to look for potential biomarkers for diagnosis of AIC using iTRAQ. A total of 133 398 spectra, 46 131 spectra identified, 12 773 distinct peptides, 1954 proteins before grouping, and 385 proteins were acquired through the analysis with ProteinPilot Software 5.0.1 search engine (Figure [2](#prca1977-fig-0002){ref-type="fig"}A).There were 217, 118, 19, and 28 proteins with a mass of 10--50 kDa, 50--100 kDa, 100--150 kDa, and more than150 kDa, respectively (Figure [2](#prca1977-fig-0002){ref-type="fig"}B). The proteins with 1--10 peptides, 11--20 peptides, 21--30 peptides, and above 30 peptides consisted of 227, 57, 31, and 68 proteins, respectively (Figure [2](#prca1977-fig-0002){ref-type="fig"}C). Protein sequence coverage with 50--100%, 30--50%, 10--30%, and under 10% variation accounted for 83, 65, 104, and 131, respectively (Figure [2](#prca1977-fig-0002){ref-type="fig"}D).

![Identification and analysis of the autoimmune cirrhosis proteome. A) Total spectra, spectra identified, distinct peptides, proteins before grouping, and proteins detected from iTRAQ proteomic analysis. B) Protein numbers were grouped based on protein mass. C) Protein numbers were distinguished on the basis of peptide numbers. D) The identified proteins were classified into pie charts according to the protein\'s sequence coverage.](PRCA-13-na-g002){#prca1977-fig-0002}

3.2. 108 Proteins Were Altered between Autoimmune Cirrhosis and Control {#prca1977-sec-0100}
-----------------------------------------------------------------------

Compared to control, a total of 108 differentially expressed proteins were identified in the AIC, these proteins met two conditions, including *p* values ≤ 0.05 and an FDR of less than 1%. Thirty‐two proteins increased by more than1.5‐fold and 76 proteins decreased to less than 0.66‐fold. Detailed information about differential expression proteins is listed in Table [1](#prca1977-tbl-0001){ref-type="table"}.

###### 

Expressions of proteins between autoimmune cirrhosis and its normal control

  **N**                                 **Accession no**.       **Protein name**                                                         **protein coverage \[%\]**   **Peptides confidence (95%)**   **Coefficient of variation**   **Ratio**   ***p*‐value**
  ------------------------------------- ----------------------- ------------------------------------------------------------------------ ---------------------------- ------------------------------- ------------------------------ ----------- ---------------
  **Immunoglobulin‐related proteins**                                                                                                                                                                                                            
  1                                     sp\|P01857\|IGHG1       Ig gamma‐1 chain C region                                                96.67                        243                             0.24                           4.17        0.011649
  2                                     sp\|P01871\|IGHM        Ig mu chain C region                                                     74.12                        67                              0.11                           8.07        0.000889
  3                                     sp\|B9A064\|IGLL5       Immunoglobulin lambda‐like polypeptide 5                                 55.61                        55                              0.07                           1.61        0.002092
  4                                     sp\|P01833\|PIGR        Polymeric immunoglobulin receptor                                        22.12                        9                               0.10                           8.81        0.000581
  5                                     sp\|P01591\|IGJ         Immunoglobulin J chain                                                   66.04                        16                              0.12                           2.38        0.003724
  6                                     sp\|P01860\|IGHG3       Ig gamma‐3 chain C region                                                96.02                        100                             0.17                           4.11        0.004568
  7                                     sp\|A0A0B4J1V0\|HV315   Immunoglobulin heavy variable 3--15                                      75.63                        12                              0.09                           1.80        0.003283
  8                                     sp\|A0A0B4J1Y8\|LV949   Immunoglobulin lambda variable 9--49                                     39.84                        3                               0.24                           1.94        0.040546
  9                                     sp\|P0CG05\|LAC2        Ig lambda‐2 chain C regions                                              96.23                        55                              0.11                           2.13        0.003149
  10                                    sp\|P01825\|HV459       Immunoglobulin heavy variable 4--59                                      46.55                        8                               0.07                           1.83        0.001417
  11                                    sp\|A0A0B4J1U7\|HV601   Immunoglobulin heavy variable 6--1                                       36.36                        4                               0.06                           1.73        0.001060
  12                                    sp\|P01714\|LV319       Immunoglobulin lambda variable 3--19                                     83.04                        6                               0.15                           1.63        0.021422
  13                                    sp\|P01701\|LV151       Immunoglobulin lambda variable 1--51                                     66.67                        12                              0.18                           2.12        0.014961
  **Complement**                                                                                                                                                                                                                                 
  14                                    sp\|P08603\|CFAH        Complement factor H                                                      49.31                        52                              0.03                           −2.85       0.000002
  15                                    sp\|P00751\|CFAB        Complement factor B                                                      63.61                        66                              0.17                           −2.46       0.000636
  16                                    sp\|P01031\|CO5         Complement C5                                                            31.92                        31                              0.01                           −2.01       0.000001
  17                                    sp\|P10643\|CO7         Complement component C7                                                  49.23                        33                              0.05                           2.38        0.000211
  18                                    sp\|P13671\|CO6         Complement component C6                                                  27.52                        23                              0.03                           −2.29       0.000008
  19                                    sp\|P05156\|CFAI        Complement factor I                                                      42.88                        18                              0.02                           −1.89       0.000003
  20                                    sp\|P06681\|CO2         Complement C2                                                            34.84                        20                              0.12                           −1.76       0.001603
  21                                    sp\|P04003\|C4BPA       C4b−binding protein alpha chain                                          41.04                        22                              0.09                           −2.02       0.000322
  22                                    sp\|P07358\|CO8B        Complement component C8 beta chain                                       25.89                        10                              0.30                           −2.58       0.002908
  23                                    sp\|Q03591\|FHR1        Complement factor H‐related protein 1                                    25.45                        8                               0.11                           −1.53       0.003152
  24                                    sp\|O43866\|CD5L        CD5 antigen‐like                                                         50.14                        13                              0.07                           3.08        0.000539
  25                                    sp\|O75636\|FCN3        Ficolin‐3                                                                22.74                        3                               0.08                           −1.69       0.000703
  26                                    sp\|P02741\|CRP         C‐reactive protein                                                       19.64                        4                               0.10                           3.58        0.001164
  27                                    sp\|P07333\|CSF1R       Macrophage colony‐stimulating factor 1 receptor                          7.92                         1                               0.12                           1.65        0.010632
  28                                    sp\|P07225\|PROS        Vitamin K‐dependent protein S                                            34.02                        19                              0.21                           −1.87       0.005370
  29                                    sp\|P04004\|VTNC        Vitronectin                                                              44.56                        22                              0.10                           −2.62       0.000103
  **Apolipoprotein**                                                                                                                                                                                                                             
  30                                    sp\|P04114\|APOB        Apolipoprotein B‐100                                                     55.53                        231                             0.01                           −2.58       0.000000
  31                                    sp\|P02647\|APOA1       Apolipoprotein A1                                                        92.88                        124                             0.07                           −4.29       0.000005
  32                                    sp\|P02649\|APOE        Apolipoprotein E                                                         76.34                        27                              0.01                           −3.45       0.000005
  33                                    sp\|O14791\|APOL1.      Apolipoprotein L1                                                        55.28                        14                              0.14                           −1.99       0.001081
  34                                    sp\|O95445\|APOM        Apolipoprotein M                                                         55.32                        6                               0.14                           −3.41       0.000087
  35                                    sp\|P02654\|APOC1       Apolipoprotein C‐I                                                       53.01                        5                               0.08                           −2.30       0.000116
  36                                    sp\|Q13790\|APOF        Apolipoprotein F                                                         16.56                        2                               0.03                           −1.57       0.000064
  37                                    sp\|P55056\|APOC4       Apolipoprotein C‐IV                                                      8.66                         1                               0.06                           −1.56       0.000404
  38                                    sp\|P08519\|APOA        Apolipoprotein(a)                                                        18.87                        4                               0.05                           −2.89       0.000006
  39                                    sp\|P04114\|APOB        Apolipoprotein B‐100                                                     55.53                        231                             0.01                           −2.58       0.000000
  40                                    sp\|P10909\|CLUS        Clusterin                                                                54.79                        35                              0.22                           −3.44       0.000320
  **Haptoglobin**                                                                                                                                                                                                                                
  41                                    sp\|P00738\|HPT         Haptoglobin                                                              90.64                        136                             0.16                           −1.71       0.004644
  41                                    sp\|P00739\|HPTR        Haptoglobin‐related protein                                              84.77                        56                              0.15                           −2.29       0.000658
  **Serum amyloid**                                                                                                                                                                                                                              
  43                                    sp\|P02743\|SAMP        Serum amyloid P‐component                                                44.84                        12                              0.26                           −2.95       0.000938
  44                                    sp\|P35542\|SAA4        Serum amyloid A‐4 protein                                                55.38                        5                               0.07                           −4.85       0.000003
  **Enzymes**                                                                                                                                                                                                                                    
  45                                    sp\|Q14624\|ITIH4       Inter‐alpha‐trypsin inhibitor heavy chain H4                             76.45                        107                             0.21                           −2.22       0.002157
  46                                    sp\|P19823\|ITIH2       Inter‐alpha‐trypsin inhibitor heavy chain H2                             55.39                        82                              0.16                           −2.36       0.000667
  47                                    sp\|P19827\|ITIH1       Inter‐alpha‐trypsin inhibitor heavy chain H1                             54.34                        64                              0.26                           −3.79       0.000333
  48                                    sp\|Q06033\|ITIH3       Inter‐alpha‐trypsin inhibitor heavy chain H3                             46.97                        30                              0.15                           1.58        0.023043
  49                                    sp\|P00747\|PLMN        Plasminogen                                                              63.33                        61                              0.06                           −2.40       0.000027
  50                                    sp\|P29622\|KAIN        Kallistatin                                                              59.72                        19                              0.25                           −2.75       0.001194
  51                                    sp\|P27169\|PON1        Serum paraoxonase/arylesterase 1                                         67.32                        25                              0.17                           −2.73       0.000372
  52                                    sp\|P36955\|PEDF        Pigment epithelium‐derived factor                                        55.98                        21                              0.07                           −1.77       0.000274
  53                                    sp\|P03952\|KLKB1       Plasma kallikrein                                                        37.46                        14                              0.15                           −2.56       0.000409
  54                                    sp\|Q96PD5\|PGRP2       N‐acetylmuramoyl‐L‐alanine amidase                                       55.21                        17                              0.32                           −2.09       0.009254
  55                                    sp\|P05154\|IPSP        Plasma serine protease inhibitor                                         27.34                        11                              0.35                           −4.04       0.000650
  56                                    sp\|Q04756\|HGFA        Hepatocyte growth factor activator                                       14.50                        7                               0.09                           −2.22       0.000170
  57                                    sp\|P15169\|CBPN        Carboxypeptidase N catalytic chain                                       21.62                        6                               0.09                           −2.13       0.000249
  58                                    sp\|P32119\|PRDX2       Peroxiredoxin‐2                                                          39.39                        8                               0.11                           1.67        0.008166
  59                                    sp\|P04180\|LCAT        Phosphatidylcholine‐sterol acyltransferase                               23.64                        7                               0.10                           −1.53       0.002907
  60                                    sp\|Q96KN2\|CNDP1       Beta‐Ala‐His dipeptidase                                                 30.37                        9                               0.05                           −2.00       0.000070
  61                                    sp\|P06276\|CHLE        Cholinesterase                                                           24.09                        7                               0.18                           −3.86       0.000108
  62                                    sp\|Q96IY4\|CBPB2       Carboxypeptidase B2                                                      23.17                        7                               0.14                           −1.71       0.003235
  63                                    sp\|P00918\|CAH2        Carbonic anhydrase 2                                                     32.31                        5                               0.09                           2.14        0.001921
  64                                    sp\|Q92820\|GGH         Gamma‐glutamyl hydrolase                                                 25.79                        3                               0.05                           −1.89       0.000075
  65                                    sp\|P08294\|SODE        Extracellular superoxide dismutase \[Cu‐Zn\]                             10.42                        2                               0.06                           −1.54       0.000547
  66                                    sp\|P80108\|PHLD        Phosphatidylinositol‐glycan‐specific phospholipase D                     33.69                        22                              0.20                           −1.96       0.003617
  **Glycoprotein**                                                                                                                                                                                                                               
  67                                    sp\|P08697\|A2AP        Alpha‐2‐antiplasmin                                                      65.78                        41                              0.09                           −1.64       0.000003
  68                                    sp\|P25311\|ZA2G        Zinc‐alpha‐2‐glycoprotein                                                78.19                        28                              0.04                           −1.59       0.001300
  69                                    sp\|P02763\|A1AG1       Alpha‐1‐acid glycoprotein 1                                              68.66                        62                              0.07                           1.98        0.000216
  70                                    sp\|P02750\|A2GL        Leucine‐rich alpha‐2‐glycoprotein                                        54.76                        19                              0.11                           1.69        0.002183
  71                                    sp\|P19652\|A1AG2       Alpha‐1‐acid glycoprotein 2                                              64.68                        29                              0.17                           −1.83       0.001083
  72                                    sp\|P12814\|ACTN1       Alpha‐actinin‐1                                                          8.97                         2                               0.16                           2.80        0.007323
  73                                    sp\|P02671\|FIBA        Fibrinogen alpha chain                                                   67.21                        209                             0.09                           −1.64       0.005676
  74                                    sp\|P02765\|FETUA       Alpha‐2‐HS‐glycoprotein                                                  75.48                        77                              0.03                           −3.54       0.000020
  75                                    sp\|P02751\|FINC        Fibronectin                                                              41.70                        80                              0.12                           −1.53       0.000105
  76                                    sp\|P02790\|HEMO        Hemopexin                                                                84.42                        90                              0.07                           −5.33       0.000009
  77                                    sp\|P05546\|HEP2        Heparin cofactor 2                                                       64.13                        44                              0.12                           −3.48       0.000009
  78                                    sp\|P02749\|APOH.       Beta‐2‐glycoprotein 1                                                    53.91                        16                                                             −3.23       0.000070
  **Hemoglobin**                                                                                                                                                                                                                                 
  79                                    sp\|P69891\|HBG1        Hemoglobin subunit gamma‐1                                               74.15                        16                              0.10                           2.02        0.002997
  80                                    sp\|P68871\|HBB         Hemoglobin subunit beta                                                  99.32                        56                              0.11                           2.09        0.003617
  81                                    sp\|P02042\|HBD         Hemoglobin subunit delta                                                 99.32                        42                              0.02                           1.51        0.000081
  **Insulin‐like growth factor**                                                                                                                                                                                                                 
  82                                    sp\|P35858\|ALS         Insulin‐like growth factor‐binding protein complex acid labile subunit   43.80                        17                              0.41                           −3.32       0.000016
  83                                    sp\|P17936\|IBP3        Insulin‐like growth factor‐binding protein 3                             28.52                        4                               0.08                           −1.51       0.001804
  **Coagulation factor**                                                                                                                                                                                                                         
  84                                    sp\|P01042\|KNG1        Kininogen‐1                                                              63.04                        73                              0.09                           −1.49       0.002136
  85                                    sp\|P00734\|THRB        Prothrombin                                                              65.11                        46                              0.07                           −2.28       0.000063
  86                                    sp\|P04196\|HRG         Histidine‐rich glycoprotein                                              58.86                        40                              0.18                           −3.35       0.000179
  87                                    sp\|P00748\|FA12        Coagulation factor XII                                                   38.21                        18                              0.28                           −1.69       0.024572
  88                                    sp\|P04275\|VWF         von Willebrand factor                                                    39.74                        12                              0.14                           3.02        0.003669
  89                                    sp\|P05160\|F13B        Coagulation factor XIII B chain                                          30.26                        12                              0.10                           −1.58       0.002278
  90                                    sp\|P12259\|FA5         Coagulation factor V                                                     11.33                        9                               0.30                           −1.85       0.016346
  91                                    sp\|P00740\|FA9         Coagulation factor IX                                                    26.03                        8                               0.05                           −1.61       0.000171
  92                                    sp\|P04070\|PROC        Vitamin K‐dependent protein C                                            18.87                        8                               0.06                           −1.61       0.000431
  **Unclassified**                                                                                                                                                                                                                               
  93                                    sp\|P02774\|VTDB        Vitamin D‐binding protein                                                76.58                        65                              0.11                           −3.74       0.000030
  94                                    sp\|P02766\|TTHY        Transthyretin                                                            86.39                        72                              0.30                           −3.94       0.000455
  95                                    sp\|P18206\|VINC        Vinculin                                                                 15.26                        9                               0.06                           1.62        0.001495
  96                                    sp\|P05452\|TETN        Tetranectin                                                              57.92                        18                              0.08                           −1.82       0.000391
  97                                    sp\|P19320\|VCAM1       Vascular cell adhesion protein 1                                         24.36                        9                               0.07                           1.99        0.001162
  98                                    sp\|P28676\|GRAN        Grancalcin                                                               12.44                        3                               0.03                           1.85        0.000095
  99                                    sp\|P49908\|SEPP1       Selenoprotein P                                                          19.69                        5                               0.05                           −2.55       0.000014
  100                                   sp\|P02760\|AMBP        Protein AMBP                                                             49.43                        24                              0.10                           −1.98       0.000495
  101                                   sp\|Q92954\|PRG         Proteoglycan 4                                                           8.55                         8                               0.07                           −1.65       0.000616
  102                                   sp\|P06396\|GELS        Gelsolin                                                                 65.60                        56                              0.19                           −7.28       0.000011
  103                                   sp\|P01019\|ANGT        Angiotensinogen                                                          55.26                        47                              0.09                           −2.62       0.000084
  104                                   sp\|P05543\|THBG        Thyroxine‐binding globulin                                               57.83                        32                              0.27                           −4.11       0.000262
  105                                   sp\|P22792\|CPN2        Carboxypeptidase N subunit 2                                             34.50                        13                              0.07                           −1.52       0.000955
  106                                   sp\|Q16610\|ECM1        Extracellular matrix protein 1                                           26.11                        7                               0.03                           −1.78       0.000031
  107                                   sp\|Q15848\|ADIPO       Adiponectin                                                              28.69                        8                               0.03                           2.79        0.000063
  108                                   sp\|P60709\|ACTB        Actin, cytoplasmic 1                                                     57.07                        21                              0.06                           1.69        0.001240

John Wiley & Sons, Ltd.

3.3. Classification of Identified Proteins {#prca1977-sec-0110}
------------------------------------------

According to GO classification system, differentially expressed proteins were distributed into categories based on molecular function, cellular components, and biological processes. For molecular functions, 32% proteins were related to response to ion binding, followed by peptidase activity (18%), enzyme regulator activity (17%), and lipid binding (8%; Figure [3](#prca1977-fig-0003){ref-type="fig"}A). For cellular components, 26% were related to extracellular region and 23% to extracellular space, followed by plasma membrane (13%) and cytoplasmic vesicle (9%; Figure [3](#prca1977-fig-0003){ref-type="fig"}B).Stress represented 18% of the biological processes, followed by immune system process (16%), vesicle‐mediated transport (15%), and signal transduction (10%; Figure [3](#prca1977-fig-0003){ref-type="fig"}C).

![GO assignment of differential expression of proteins in autoimmune cirrhos**is**. A) Molecular function. B) Cellular component. C) Biological processes.](PRCA-13-na-g003){#prca1977-fig-0003}

3.4. KEGG Pathway Analysis of Identified Proteins {#prca1977-sec-0120}
-------------------------------------------------

As shown in Table [2](#prca1977-tbl-0002){ref-type="table"}, the 108 differential expression proteins were further investigated using the KEGG database, and they were found to be enriched in complement and coagulation cascades (14.8%), *Staphylococcus aureus* infection (4.4%), systemic lupus erythematosus (3.8%), regulation of actin cytoskeleton (3.3%), focal adhesion (3.3%), and African trypanosomiasis (2.7%).

###### 

KEGG enrichment analysis of differential expression of proteins

  **KEGG pathway**                       **Number of proteins**   **Pathway ID**
  -------------------------------------- ------------------------ ----------------
  Complement and coagulation cascades    27                       hsa04610
  Staphylococcus aureus infection        8                        hsa05150
  Systemic lupus erythematosus           7                        hsa05322
  Regulation of actin cytoskeleton       6                        hsa04810
  Focal adhesion                         6                        hsa04510
  African trypanosomiasis                5                        hsa05143
  Amoebiasis                             4                        hsa05146
  Prion diseases                         4                        hsa05020
  Leukocyte transendothelial migration   4                        hsa04670
  PI3K‐Akt signaling pathway             4                        hsa04151
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3.5. Protein--Protein Interaction Network {#prca1977-sec-0130}
-----------------------------------------

Biological systems can be regulated as complex network systems with many interactions among the components in different pathways. In order to better understand the pathogenic mechanisms in AIC, the protein interaction network for the identified variable proteins was constructed by STRING. From the network diagram (Figure [4](#prca1977-fig-0004){ref-type="fig"}), many proteins were at the core of the "traffic link," such as vWF, IFGALS, apoA1, apoE, and so on, which suggest that they may play an important role in the development of AIC.

![Interaction network analysis of differential expression of proteins. In this network, nodes are proteins, lines represent functional associations between proteins, and different line colors represent the types of evidence for the predicted functional association. A red line indicates the presence of fusion evidence; a green line indicates neighborhood evidence; a blue line indicates co‐ocurrence evidence; a purple line indicates experimental evidence; a yellow line indicates text mining evidence; a light blue line indicates database evidence; a black line indicates coexpression evidence.](PRCA-13-na-g004){#prca1977-fig-0004}

3.6. Validation of Candidate Biomarkers Using Western Blot {#prca1977-sec-0140}
----------------------------------------------------------

The 108 proteins which were identified using iTRAQ were classified into ten categories, based on protein function and eight significant proteins (including apoA1, apoE, vWF, IFGALS, gelsolin, adiponectin, TTR, pIgR) were verified further using western blot (Table [3](#prca1977-tbl-0003){ref-type="table"}), their MS/MS spectrogram were added to show the iTRAQ quantification (Figure [5](#prca1977-fig-0005){ref-type="fig"}). Western blot results showed that compared with the normal controls, the ratio of vWF, adiponectin, pIgR was, respectively, increased 2.43 (*p* \< 0.0001), 2.82 (*p* \< 0.0001), 1.66 (*p* \< 0.0001) in AIC, 1.39 (*p* \< 0.001), 1.46 (*p* \< 0.001), 2.72 (*p* \< 0.0001) in AIH, 1.27 (*p* \< 0.001), 1.21 (*p* \< 0.05), 1.28 (*p* \< 0.01) in HBV and 1.38 (*p* \< 0.001), 1.40 (*p* \< 0.001), 1.30 (*p* \< 0.01) in HCV. However, the ratio of IFGALS, TTR, apoA1, apoE, gelsolin was, respectively, decreased to 0.63 (*p* \< 0.0001), 0.68 (*p* \< 0.0001), 0.78 (*p* \< 0.01), 0.70 (*p* \< 0.001), 0.83 (*p* \< 0.001) in AIC, 0.89 (*p* \< 0.01), 0.85 (*p* \< 0.0001), 0.90 (*p* \> 0.05), 0.95 (*p* \> 0.05), 0.75 (*p* \< 0.0001) in AIH, 0.86 (*p* \< 0.001), 0.90 (*p* \< 0.01), 0.88 (*p* \< 0.01), 0.75 (*p* \< 0.001), 0.88 (*p* \< 0.01) in HBV and 0.98 (*p* \> 0.05), 0.95 (*p* \< 0.01), 0.95 (*p* \> 0.05), 0.94 (*p* \< 0.05), 0.93 (*p* \< 0.01) in HCV (Figure [6](#prca1977-fig-0006){ref-type="fig"}).Western blot results showed the same trend of change with iTRAQ methods in AIC, which confirmed the reliability of the iTRAQ results.

###### 

Categories of significant differential expression of proteins in autoimmune cirrhosis

  N   Accession no.       Protein name                                                             Ratio   *p*‐value   Function
  --- ------------------- ------------------------------------------------------------------------ ------- ----------- ----------------------------------------------------
  1   sp\|P04275\|VWF     von Willebrand factor                                                    3.02    0.003669    Hypercoagulability and thrombosis
  2   sp\|Q15848\|ADIPO   Adiponectin                                                              2.79    0.000063    Insulin‐sensitizing adipokine
  3   sp\|P35858\|ALS     Insulin‐like growth factor‐binding protein complex acid labile subunit   −3.32   0.000016    Increasing IGF half‐life and vascular localization
  4   sp\|P02766\|TTHY    Transthyretin                                                            −3.94   0.000455    Transport of thyroxine and retinol
  5   sp\|P01833\|PIGR    Polymeric immunoglobulin receptor                                        8.81    0.000581    Transport of pIg (particular dimeric IgA)
  6   sp\|P02647\|APOA1   Apolipoprotein AI                                                        −4.29   0.000005    Lipoprotein metabolism
  7   sp\|P02649\|APOE    Apolipoprotein E                                                         −3.45   0.000005    Lipoprotein metabolism
  8   sp\|P06396\|GELS    Gelsolin                                                                 −7.28   0.000011    Actin regulator
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![MS/MS spectrum to show the iTRAQ quantification. A representative MS/MS spectrum showed peptide signatures for vWF, adiponectin, IFGALS, transthyretin, pIgR, apoA1, apoE, and gelsolin. Ratios of iTRAQ tags indicate the relative abundance of the eight proteins individually in autoimmune cirrhosis serum compared to corresponding control samples.](PRCA-13-na-g005){#prca1977-fig-0005}

![Western blot validation of selected proteins in the iTRAQ data set. Representative western blots for three proteins validated in serum with vWF, adiponectin, IFGALS, pIgR, transthyretin, apoA, apoE, and gelsolin. Data are expressed as the mean. Control (*n* = 120), AIH (*n* = 90), AIC (*n* = 90), HBV (*n* = 120), HCV (*n* = 120). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](PRCA-13-na-g006){#prca1977-fig-0006}

3.7. ROC Curve Analysis {#prca1977-sec-0150}
-----------------------

To evaluate the specificity and sensitivity of each marker and their combination in the diagnosis of AIC and AIH, we conducted ROC analysis. The accuracy of the area under the ROC curve was assessed as follows: 0.9--1 = excellent, 0.8--0.9 = good, 0.7--0.8 = fair, 0.6--0.7 = poor, and \<0.6 = not useful. In AIC, ROC analysis results are as follows: vWF (AUC: 0.880; 95% CI 0.825--0.934), adiponectin (AUC: 0.895; 95% CI 0.845--0.944), pIgR (AUC: 0.757; 95% CI 0.690--0.824), IFGALS (AUC: 0.829; 95% CI 0.769--0.888), TTR (AUC: 0.814; 95% CI 0.750--0.877), apoA1 (AUC: 0.700; 95% CI 0.627--0.773), apoE (AUC: 0.788; 95% CI 0.722--0.854), gelsolin (AUC: 0.697; 95% CI 0.626--0.768). The combination of these eight proteins displays a significant predictive value for AIC (AUC: 1.000; 95% CI 1.000--1.000) (Figure [7](#prca1977-fig-0007){ref-type="fig"}A). In AIH, ROC analysis results are as follows: vWF (AUC: 0.770; 95% CI 0.702--0.839), adiponectin (AUC: 0.737; 95% CI 0.668--0.807), pIgR (AUC: 0.880; 95% CI 0.824--0.936), IFGALS (AUC: 0.617; 95% CI 0.540--0.694), TTR (AUC: 0.697; 95% CI 0.624--0.771), apoA1 (AUC: 0.567; 95% CI 0.488--0.645), apoE (AUC: 0.587; 95% CI 0.506--0.667), gelsolin (AUC: 0.770; 95% CI 0.704--0.837). The combination of these eight proteins also displays a significant predictive value for AIH (AUC: 0.994; 95% CI 0.989--1.000; Figure [7](#prca1977-fig-0007){ref-type="fig"}B).

![Receiver operating characteristic (ROC) curves for selected proteins in autoimmune cirrhosis and autoimmune hepatitis. ROC analysis for vWF alone, adiponectin alone, IFGALS alone, pIgR alone, transthyretin alone, apoA alone, apoE alone, gelsolin alone, and their combination in the diagnosis of AIC and AIH.](PRCA-13-na-g007){#prca1977-fig-0007}

4. Discussion {#prca1977-sec-0160}
=============

AIC seriously impairs human\'s life and health. Once the clinical symptoms appear, it has changed to late stage with many complications which seriously endanger the lives of patients, resulting in missing the best time for treatment. Therefore, early diagnosis is necessary for assessing the risk of progression and planning the appropriate treatment. Unfortunately, we lack the means for early diagnosis at the present stage.

In the present study, we took advantage of iTRAQ‐based proteomics which has the advantages of adequate sensitivity, high reproducibility, and wide linear dynamic range over traditional proteomics,[14](#prca1977-bib-0014){ref-type="ref"} to identify diagnostic markers of AIC. The majority of the differentially expressed proteins are involved in the immunoglobulin system, complement activation system, lipid metabolism system, and coagulation system.

vWF\'s primary function is binding to factor VIII, which is important in platelet adhesion to wound sites, so vWF plays a major role in blood coagulation.[15](#prca1977-bib-0015){ref-type="ref"} Recent research suggests that vWF is also involved in the formation of blood vessels themselves, which would explain why some people with vWF disease develop vascular malformations that can bleed excessively.[16](#prca1977-bib-0016){ref-type="ref"} The biological breakdown of vWF is largely mediated by the enzyme [ADAMTS13](http://ADAMTS13) which is synthesized mainly in liver cells,[17](#prca1977-bib-0017){ref-type="ref"} so the elevation of vWF may be involved in vascular remodeling leading to gastrointestinal bleeding tendency (one of the most serious complications) in AIC. Compared with the control group, vWF increased to 1.39 times in AIH and continued to increase to 2.43 times in AIC. However, there was relatively low expression in HBV and HCV. Meanwhile, ROC analysis (AUC: 0.880; 95% CI 0.825--0.934) showed that vWF could be a better indicator of AIC, and was also a better dynamic observation index in different stages of autoimmune liver disease.

Adiponectin is the major insulin‐sensitizing adipokine, mainly secreted by hepatocytes and adipocytes. Adiponectin exhibits anti‐inflammatory, anti‐hyperglycemic, and anti‐atherogenic properties, which could be beneficial in the prevention and treatment of disorders associated with overweight.[18](#prca1977-bib-0018){ref-type="ref"} Adiponectin also plays a pivotal role in metabolic liver disease, it exerts direct effects on hepatocytes,[19](#prca1977-bib-0019){ref-type="ref"} regulates two metabolic pathways, anti‐inflammatory peroxisome proliferator‐activated receptor α, and fatty acid oxidation, suggesting that adiponectin may potentially play hepatoprotective roles against liver fibrosis and cirrhosis.[20](#prca1977-bib-0020){ref-type="ref"} Compared with the control group, adiponectin increased to 1.46 times in AIH and continued to rise to 2.82 times in AIC. Meanwhile, ROC analysis (AUC: 0.895; 95% CI 0.845--0.944) showed that adiponectin could be a better indicator of AIC, and was also a better dynamic observation target in different stages of autoimmune liver disease.

IGFALS is synthesized mostly by the plasma cells of the liver. IGFALS is able to combine with insulin‐like growth factors (IGFs) to form a heterologous protein complex, which can prolong the half‐life of IGFs in the blood.[21](#prca1977-bib-0021){ref-type="ref"} AIC resulted in a significant decrease in the synthesis of IGFALS, which may be due to downregulation expression of the growth hormone receptor or due to an increase of growth hormone rejection. Comparing with the control group, it is shown that IGFALS dropped to 0.89 in AIH, and later went on to decrease to 0.63 in AIC. Besides, ROC analysis (AUC: 0.829; 95% CI 0.769--0.888) reflected that IGFALS could be a better indicator for AIC.

Autoimmune hepatitis (AIH) is one of the autoimmune diseases and is characterized by increases in the levels of γ‐globulins and immunoglobulin G in the blood.[22](#prca1977-bib-0022){ref-type="ref"} The experimental results showed different subtypes of immunoglobulin and immunoglobulin receptor increased in different degrees in the serum. Polymeric immunoglobulin receptor (pIgR) is a transmembrane glycoprotein, selectively expressed by mucosal and glandular epithelial cells. pIgR mediates transport of pIg (in particular dimeric IgA) into external secretions, which provide the first line of adaptive immune defense against ingested, inhaled, and sexually transmitted pathogens.[23](#prca1977-bib-0023){ref-type="ref"} The key regulator of pIgR expression is cytokines, such as INF‐γ, TNF, and IL‐1.[24](#prca1977-bib-0024){ref-type="ref"} In comparison with the control group, pIgR increased to 2.7 times in AIH and lowered to 1.66 times in AIC. ROC analysis (AUC: 0.880; 95% CI 0.824--0.936) showed that pIgR could be a better indicator of AIH as well as a better dynamic observation index in different courses of the autoimmune liver disease.

TTR, known as prealbumin, has a major role in the transport of thyroxine and retinol as a transporter.[25](#prca1977-bib-0025){ref-type="ref"} Serum TTR might be a sensitive indicator in assessing liver dysfunction in acute liver diseases.[26](#prca1977-bib-0026){ref-type="ref"} Transferrin was also reduced in chronic hepatitis C and hepatitis B.[27](#prca1977-bib-0027){ref-type="ref"} Compared to the control group, TTR dropped to 0.85 in AIH, and later continued to decrease to 0.68 in AIC. In the meanwhile, ROC analysis (AUC: 0.814; 95% CI 0.750--0.877) obviously indicated that TTR could be a good indicator of AIC.

Apolipoprotein is mostly synthesized in the liver,[28](#prca1977-bib-0028){ref-type="ref"} which plays an important role in lipoprotein metabolism, including five subtypes apoA, apoB, apoC, apoD, apoE. apoE transports lipoproteins, fat‐soluble vitamins, and cholesterol into the lymph system and then into the blood. apoE was initially recognized for its importance in lipoprotein metabolism and cardiovascular disease. More recently, it has been studied for its role in several biological processes, including Alzheimer\'s disease (AD),[29](#prca1977-bib-0029){ref-type="ref"} immunoregulation, and cognition.[30](#prca1977-bib-0030){ref-type="ref"} In the field of immune regulation, a growing number of studies point to apoE\'s interaction with many immunological processes, including suppressing T cell proliferation, macrophage functioning regulation, lipid antigen presentation facilitation (by CD1) to natural killer T cell as well as modulation of inflammation and oxidation.[31](#prca1977-bib-0031){ref-type="ref"} apoA1 is the major protein component of HDL particles, apoA1 (the ratio apoB‐100/apoA1) is often used as a biomarker for prediction of cardiovascular diseases.[32](#prca1977-bib-0032){ref-type="ref"} The extent of liver damage is directly proportional to the low level of apoE and apoA1. So serum apolipoprotein can be used as an important indicator to assess the severity of cirrhosis. However, ROC analysis apoA1 (AUC: 0.700; 95% CI 0.627--0.773), apoE (AUC: 0.788; 95% CI 0.722--0.854) in AIC, apoA1 (AUC: 0.567; 95% CI 0.488--0.645), apoE (AUC: 0.587; 95% CI 0.506--0.667) in AIH showed apoA1 and apoE were not ideal diagnostic indicators.

Gelsolin, a Ca^2+^‐regulated actin filament severing and capping protein, is a highly conserved, polyfunctional regulator of cell structure and metabolism.[33](#prca1977-bib-0033){ref-type="ref"} Previous research demonstrated that gelsolin was prevalently expressed in a variety of cells and was decreased in various liver diseases,.[34](#prca1977-bib-0034){ref-type="ref"} However, ROC analysis (AUC: 0.697; 95% CI 0.626--0.768 in AIC and AUC: 0.770; 95% CI 0.704--0.837 in AIH) showed gelsolin was also not an ideal diagnostic indicator.

In the study, we first implemented iTRAQ technique to identify vWF, adiponectin, IFGALS, and TTR as candidate biomarkers in AIC, which will provide a useful basis for further analysis of the pathogenic mechanism.
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